Core Viewpoint - Applied Digital Corporation will host a conference call on July 30, 2025, to discuss its operations and financial results for the fiscal fourth quarter and full year ended May 31, 2025 [1][2]. Company Overview - Applied Digital Corporation (Nasdaq: APLD) specializes in designing, building, and operating next-generation digital infrastructure for High-Performance Computing (HPC) applications [4]. - The company focuses on creating purpose-built facilities that support accelerated computing, secure digital hosting, and services like CSaaS and GPU-as-a-Service [4]. - Applied Digital aims to support demanding workloads in AI, machine learning, blockchain, and HPC, leveraging its expertise and robust power pipeline [4]. Conference Call Details - The conference call is scheduled for July 30, 2025, at 5:00 p.m. Eastern Time, with a prepared remarks segment followed by a Q&A session [2]. - Participants are encouraged to dial in approximately 10 minutes before the start time, and a replay of the call will be available from July 30, 2025, through August 7, 2025 [3].

Core Insights - AmpliTech Group, Inc. has appointed Aamir Sultan to its Board of Advisors, effective immediately, enhancing its strategic capabilities in technology and government relations [1][4]. Company Overview - AmpliTech Group, Inc. specializes in designing, developing, and manufacturing advanced signal processing components for various communication networks, including satellite, Public and Private 5G, and 6G systems [1][5]. - The company operates through five divisions, focusing on radio frequency (RF) microwave components and 5G network solutions, serving global markets such as telecommunications, defense, and quantum computing [5]. Aamir Sultan's Expertise - Aamir Sultan brings over 20 years of experience in Artificial Intelligence (AI), Machine Learning (ML), and IoT modernization, currently leading IT system transformations in Suffolk County, NY [2]. - His political and regulatory experience includes serving as a Delegate from New York and a former candidate for the New York State Assembly, providing AmpliTech with strategic access to business and technology development [3]. Strategic Implications - Sultan's dual expertise in technology infrastructure and government affairs is expected to support AmpliTech's expansion into federal opportunities and next-generation network development [4]. - His role will involve providing insights into public-sector digital transformation and emerging regulatory frameworks, aiding AmpliTech's mission in wireless and defense communications [4].

Financial Data and Key Metrics Changes - Total revenue for the first quarter was $52.4 million, representing a 25% growth from the same period last year [22] - MRD revenue grew 34% year-over-year to $43.7 million, with clinical and pharma contributions of 65% and 35% respectively [22] - Sequencing gross margin improved by 17 percentage points year-over-year to 62% [8][22] - Operating expenses decreased by 9% to $82 million, driven by lower R&D spending [23] - Cash burn for the quarter was $23 million, a 38% improvement compared to the same period last year [8] Business Line Data and Key Metrics Changes - ClonoSEQ clinical revenue grew 55% year-over-year, with test deliveries reaching over 23,000, a 36% increase [10] - Average selling price (ASP) for ClonoSEQ tests in the US increased by 14% to over $1,220 per test [13] - MRD Pharma revenue grew 11% year-over-year, with $4.5 million recognized in regulatory milestones [14] Market Data and Key Metrics Changes - The number of ordering healthcare providers grew 31% year-over-year, now exceeding 3,400 [12] - Blood-based testing contributed 44% of MRD tests in the US, up from 39% a year ago [11] Company Strategy and Development Direction - The company is focused on increasing the lifetime value of each clonoSEQ Medicare patient and expanding its market presence through EMR integrations [9][12] - Strategic goals include achieving over 45% of clonoSEQ testing done in blood and launching new initiatives in the second half of the year [16] - The company aims to be adjusted EBITDA positive in the second half of the year [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving raised full-year guidance due to strong first-quarter performance and sustained momentum [29] - The company has minimal exposure to tariffs and NIH funding pressures, providing a solid cash position of $233 million [9] Other Important Information - The company is on track to lower its full-year total operating expense guidance to a range of $335 million to $345 million [26] - Full-year cash burn guidance has been lowered to a range of $50 million to $60 million [27] Q&A Session Summary Question: Specific indications seeing growth and contribution trends - Management noted strong sequential growth across all indications, particularly in lymphoma indications like DLBCL and MCL [32] Question: Updates on EMR integration and larger accounts - Management reported significant growth in accounts integrated for over a year, with some larger accounts showing an average quarter-over-quarter growth of 27% [37] Question: Drivers of clonoSEQ volume growth - Management indicated that growth was driven by non-Hodgkin's lymphoma indications and the acceleration of EMR integrations [42] Question: Milestone payments and funnel growth - Management confirmed that more milestones are becoming available, providing clarity and confidence in the 2025 outlook [48] Question: Pricing and contracting discussions - Management emphasized a disciplined approach to pricing, ensuring contracted rates are close to Medicare rates [51] Question: Frequency of testing in clinical trials - Management acknowledged increased interest in more frequent testing, particularly in multiple myeloma trials [58] Question: Operational efficiencies from EMR integrations - Management noted potential operational efficiencies from EMR integrations, with significant reductions in callbacks reported by integrated accounts [68] Question: NeoGenomics partnership progress - Management provided updates on the partnership, focusing on optimizing the broader national launch based on insights gained from phase one accounts [115]

Financial Data and Key Metrics Changes - Total revenue for the first quarter was $52.4 million, representing a 25% growth from the same period last year [19] - MRD revenue grew 34% year-over-year to $43.7 million, with clinical and pharma contributions of 65% and 35% respectively [19] - Sequencing gross margin improved by 17 percentage points year-over-year to 62% [6][21] - Operating expenses decreased by 9% to $82 million, driven by lower R&D spending [21] - Cash burn for the quarter was $23 million, a 38% improvement compared to the same period last year [6] Business Line Data and Key Metrics Changes - ClonoSEQ clinical revenue grew 55% year-over-year, with test volume reaching over 23,000, a 36% increase [8] - Blood-based testing contributed 44% of MRD tests in the US, up from 39% a year ago [9] - MRD Pharma revenue grew 11% year-over-year, with $4.5 million recognized in regulatory milestones [12] - Immune medicine revenue was $8.7 million, down 6% from a year ago, primarily due to a decrease in Genentech amortization [20] Market Data and Key Metrics Changes - The number of ordering healthcare providers grew 31% year-over-year, now exceeding 3,400 [10] - EMR integrations accelerated, with 27 live integrations including five of the top 10 accounts [10] - The contribution of DLBCL and MCL in MRD tests increased to 12% from 10% a year ago [9] Company Strategy and Development Direction - The company is focused on increasing the lifetime value of each clonoSEQ Medicare patient and expanding its market presence in blood-based testing [6][14] - Strategic goals include achieving over 45% of clonoSEQ testing done in blood, launching Onco EMR with Flatiron, and beginning phase one testing with NeoGenomics [14] - The company aims to be adjusted EBITDA positive in the second half of the year [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving raised full-year guidance due to strong first-quarter performance and sustained momentum [24] - The company anticipates approximately 30% growth in clonoSEQ test volumes for 2025 compared to 2024 [22] - Management noted minimal exposure to tariffs and NIH funding pressures, highlighting a solid cash position of $233 million [7] Other Important Information - The company is raising its full-year MRD revenue guidance to a range of $180 million to $190 million [22] - Operating expense guidance has been lowered to a range of $335 million to $345 million [23] - Cash burn guidance has also been reduced to a range of $50 million to $60 million [23] Q&A Session Summary Question: Specific indications seeing growth and contribution trends - Management noted strong sequential growth across all indications, particularly in lymphoma indications like DLBCL and MCL [26][27] Question: Updates on EMR integration and growth quantification - Management reported significant growth in accounts that have been live for at least a year, with six of seven accounts exceeding 75% year-over-year growth [30][31] Question: Drivers of clonoSEQ volume growth and weather impact - Management confirmed no notable weather impacts and attributed growth to DLBCL and MCL, along with EMR integrations [36][37] Question: Milestone payments and funnel growth - Management indicated that more milestones are becoming available, providing clarity and confidence in the 2025 outlook [41][43] Question: Pricing and contracting discussions - Management emphasized discipline in pricing, ensuring contracted rates are close to Medicare rates [45][46] Question: Multiple myeloma trials and testing intervals - Management acknowledged increased interest in more frequent testing, particularly in multiple myeloma and other indications [50][52] Question: Technology improvements and addressing market adjacencies - Management is actively looking for ways to enhance technology and improve sensitivity in assays [54][56] Question: EMR integration and operational efficiencies - Management noted potential operational efficiencies from EMR integrations, with significant reductions in callbacks reported [60][61] Question: NeoGenomics partnership progress - Management provided updates on the selection of phase one accounts and preparations for the pilot launch in the second half of the year [106][108]

Core Viewpoint - The release of the HBM4 specification by JEDEC is a significant advancement for AI training hardware developers, offering enhanced memory performance and density crucial for processing large datasets and complex computations in applications like generative AI and high-performance computing [1][3]. Summary by Sections HBM4 Overview - HBM4 provides a memory performance of 2TB/s and a density of up to 64GB, which is essential for applications requiring efficient processing of large datasets [1][3]. - The bandwidth of HBM4 is double that of HBM3, achieved by increasing the frequency to 8Gb/s and doubling the data width to 2048 bits [3]. Key Features of HBM4 - Higher Bandwidth: HBM4 supports over 1TB/s per stack, significantly surpassing DDR4's 25.6GB/s per module, which is critical for workloads needing rapid data access [7]. - Higher Memory Density: HBM4's vertical stacking architecture allows for greater memory density in a smaller physical footprint compared to traditional DDR memory [7]. - Energy Efficiency: HBM4 typically consumes 40% to 50% less power than DDR4 at equivalent bandwidths, enhancing performance while reducing power consumption [7]. Applications of HBM4 - HBM4 plays a crucial role in AI and machine learning applications that require high-speed processing of massive datasets, improving the performance of AI accelerators [9]. - In high-performance computing and scientific simulations, HBM4 significantly accelerates computation speeds and reduces memory bottlenecks, enhancing the efficiency of supercomputers and HPC clusters [9]. Challenges in HBM4 Deployment - High Production Costs: The advanced architecture of HBM4 results in higher manufacturing costs compared to traditional memory solutions [12]. - Complex System Integration: HBM4 requires proximity to CPUs or GPUs, complicating system design and integration for manufacturers [12]. - Thermal Management Issues: The high data transfer rates generate more heat, necessitating sophisticated cooling systems to maintain stable performance [13]. Workflow Advantages of HBM4 - HBM4 supports advanced multitasking environments, accelerating data processing between CPUs and memory, which is beneficial for running multiple virtual machines or complex workflows [14]. - Its compact design allows for higher memory density in space-constrained high-performance systems, providing greater flexibility in system design [14]. Future Trends of HBM4 - The future development of HBM4 may focus on integration with emerging technologies like quantum computing and next-generation AI accelerators, enhancing its role in supporting innovative applications [16]. - Efforts to reduce production costs and simplify system integration are expected to drive broader adoption in commercial and consumer markets [16].

Core Insights - NVIDIA Corp. dominates the GPU market with over 92% share, benefiting significantly from the rising demand for AI infrastructure, with next-generation Blackwell GPUs sold out for the next 12 months [1] - Application-specific integrated circuits (ASICs) are emerging as efficient alternatives to GPUs for specialized AI tasks, with companies like Broadcom and Marvell Technology gaining traction in this space [2][3] Group 1: NVIDIA and the GPU Market - NVIDIA's GPUs are essential for AI, machine learning, and high-performance computing tasks, particularly in data centers [1] - The company is experiencing unprecedented demand, leading to a complete sell-out of its next-generation GPUs for a year [1] Group 2: Broadcom's Position in AI Infrastructure - Broadcom Inc. holds over 50% market share in the ASICs industry and specializes in high-performance networking solutions crucial for AI data centers [4] - The company reported a 77% year-over-year growth in AI-centric revenues, reaching $4.1 billion in FQ1 2025, surpassing forecasts [7] - Broadcom's gross margins were 79.1%, contributing to a total revenue increase of 24.7% year-over-year to $14.92 billion, exceeding analyst estimates [8] Group 3: Marvell Technology's ASICs Business - Marvell Technology focuses on data center interconnects and has developed advanced Serializer-Deserializer technology to enhance data movement within AI systems [10] - The company reported a 27.4% year-over-year revenue increase to $1.82 billion, with data center revenues climbing 75% due to the AI boom [12] - Marvell's custom ASICs are optimized for AI workloads, and the company has developed over 2,500 ASICs in the past 25 years [11]

As filed with the Securities and Exchange Commission on June 20, 2023 ____________________ VERSUS SYSTEMS INC. (Translation of Registrant's Name into English) ____________________ Registration No. 333-271771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Not Applicable British Columbia 7374 Not Applicable (State or other Jurisdiction of (Primary Standard Industrial Classification ...

(Exact Name of Registrant as Specified in Its Charter) ____________________ Not Applicable (Translation of Registrant's Name into English) ____________________ (State or other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial As filed with the Securities and Exchange Commission on May 9, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ VERSUS SYSTE ...